Aurinia Pharmaceuticals Inc (AUPH)
$15.85
$0.19
(1.21%)
As on 11-Jun-2026 16:00EDT
Market cap
$2,037 Mln
Revenue (TTM)
$298 Mln
P/E Ratio
7.3
P/B Ratio
3.7
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
11.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$2.2
-
Face value
--
-
Shares outstanding
128,601,671
10 Years Aggregate
CFO
$-550.16 Mln
EBITDA
$-666.04 Mln
Net Profit
$-787.15 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aurinia Pharmaceuticals (AUPH)
| -0.6 | 4.1 | 7.1 | 94.5 | 16.6 | 4.6 | 19.4 |
|
BSE Sensex*
| -11.8 | -1.8 | -2.9 | -9.5 | 6.0 | 7.3 | 10.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Aurinia Pharmaceuticals (AUPH)
| 77.6 | 108.1 | -81.1 | 65.4 | -31.7 | 197.1 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aurinia Pharmaceuticals (AUPH)
|
15.9 | 2,037.1 | 298.3 | 298.2 | 47.7 | 63.9 | 7.3 | 3.7 |
| 5.3 | 1,716.2 | 79.2 | -144.0 | -259.5 | -15.1 | -- | 2.1 | |
| 5.5 | 303.9 | 0.0 | -35.1 | 131,201.1 | -71 | -- | 6.4 | |
| 5.7 | 48.6 | 0.1 | -10.4 | -20,782.3 | -92.2 | -- | 34.6 | |
| 8.9 | 302.2 | 51.0 | -8.4 | -13.3 | -- | -- | 8.4 | |
| 1.6 | 5.2 | 663.9 | -9.9 | -1.5 | -86 | -- | 0.8 | |
| 1.3 | 153.1 | 1.8 | -68.4 | -3,544.8 | -241.8 | -- | 4.4 | |
| 52.2 | 5,000.5 | 0.0 | -383.2 | -- | -40.4 | -- | 3.7 |
Shareholding Pattern
View DetailsAbout Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral... therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada. Read more
-
President, CEO & Director
Mr. Peter S. Greenleaf M.B.A.
-
President, CEO & Director
Mr. Peter S. Greenleaf M.B.A.
-
Headquarters
Edmonton, AB
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Aurinia Pharmaceuticals (AUPH)
What is the current share price of Aurinia Pharmaceuticals Inc (AUPH) Today?
The share price of Aurinia Pharmaceuticals Inc (AUPH) is $15.85 (NASDAQ) as of 11-Jun-2026 16:00 EDT. Aurinia Pharmaceuticals Inc (AUPH) has given a return of 16.63% in the last 3 years.
What is the current PB & PE ratio of Aurinia Pharmaceuticals Inc (AUPH)?
The P/E ratio of Aurinia Pharmaceuticals Inc (AUPH) is 7.33 times as on 05-Jun-2026.
The P/B ratio of Aurinia Pharmaceuticals Inc (AUPH) is 3.71 times as on 05-Jun-2026, a 9 discount to its peers’ median range of 4.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
7.72
|
3.81
|
|
2024
|
227.93
|
3.47
|
|
2023
|
-16.48
|
3.40
|
|
2022
|
-5.67
|
1.51
|
|
2021
|
-16.30
|
6.16
|
What is the 52 Week High and Low of Aurinia Pharmaceuticals Inc (AUPH)?
The 52-week high and low of Aurinia Pharmaceuticals Inc (AUPH) are Rs 16.88 and Rs 7.29 as of 12-Jun-2026.
What is the market cap of Aurinia Pharmaceuticals Inc (AUPH)?
Aurinia Pharmaceuticals Inc (AUPH) has a market capitalisation of $ 2,037 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Aurinia Pharmaceuticals Inc (AUPH)?
Before investing in Aurinia Pharmaceuticals Inc (AUPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.